Priyadharshini Thangavelu

Priyadharshini Thangavelu

Auto-generated profile, based on publicly available information

Priyadharshini Thangavelu

Department of Biochemistry, Bharathiar University, Coimbatore, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2025 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Open access
PTPriyadharshini Thangavelu
Priyadharshini Thangavelu
KGKaavya Gunasekaran
Kaavya Gunasekaran
SPSenthilkumar Periyathambi
Senthilkumar Periyathambi
AHAbeer Hashem
Abeer Hashem
NANOUF ALOTAIBI
NOUF ALOTAIBI
SSSuja Samiappan
Suja Samiappan
The study aimed to optimize and develop novel PEGylated co-loaded nanoliposome entrapped with paclitaxel (PTX) and 6-gingerol (Gn) (PEG-Lipo-PTX-Gn) by response surface methodology (RSM) approach to prevent the diffusion and resistant-related issues of PTX in oncotherapy. Physiochemical characterization studies results revealed that the prepared PEG-Lipo-PTX-Gn attained optimum particle size, shape, charge, polydispersity index (PDI) as well as showed synergistic entrapment of PTX and Gn, sustained drug release, better colloidal stability and structural integrity. PEG-Lipo-PTX-Gn exhibited a noteworthy antiproliferative effect, apoptotic percentage and a higher proportion of G2/M cell cycle arrest in MDA-MB-231 and A549 cell lines. Meanwhile, no significant toxicity was observed in normal cell lines (HEK 293 kidney embryonic cells and L929 fibroblast cells). Another testament to its efficacy is the dramatic decline in Bcl-2 levels in the PEG-Lipo-PTX-Gn-treated group. Hence, optimized PEG-Lipo-PTX-Gn could be a promising novel approach in cancer treatment regimens.